Ventyx Biosciences, Inc. financial data

Symbol
VTYX on Nasdaq
Industry
Pharmaceutical Preparations
Location
12790 El Camino Real, Suite 200, San Diego, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.9K % +23.6%
Debt-to-equity 8.77 % -2.45%
Return On Equity -48.2 % +23.3%
Return On Assets -44.3 % +23.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 71.1M shares +0.9%
Common Stock, Shares, Outstanding 71.1M shares +20.1%
Entity Public Float 142M USD -89.1%
Common Stock, Value, Issued 7K USD +16.7%
Weighted Average Number of Shares Outstanding, Basic 68.5M shares +17%
Weighted Average Number of Shares Outstanding, Diluted 68.5M shares +17%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 117M USD -33.4%
General and Administrative Expense 31.4M USD -2.42%
Operating Income (Loss) -148M USD +28.6%
Nonoperating Income (Expense) 13.3M USD -11.3%
Net Income (Loss) Attributable to Parent -135M USD +30%
Earnings Per Share, Basic -1.97 USD/shares +40.3%
Earnings Per Share, Diluted -1.97 USD/shares +40.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 27.3M USD -47.1%
Marketable Securities, Current 190M USD -5.27%
Cash, Cash Equivalents, and Short-term Investments 253M USD +0.28%
Assets, Current 230M USD -13.1%
Property, Plant and Equipment, Net 614K USD -19.4%
Operating Lease, Right-of-Use Asset 9.67M USD -16%
Other Assets, Noncurrent 59K USD -42.2%
Assets 277M USD -0.41%
Accounts Payable, Current 3.13M USD -45.6%
Employee-related Liabilities, Current 5.35M USD -30.9%
Accrued Liabilities, Current 8.59M USD -44.6%
Liabilities, Current 12.8M USD -42.6%
Operating Lease, Liability, Noncurrent 9.74M USD -15.3%
Liabilities 22.5M USD -33.3%
Accumulated Other Comprehensive Income (Loss), Net of Tax 157K USD
Retained Earnings (Accumulated Deficit) -554M USD -32.2%
Stockholders' Equity Attributable to Parent 254M USD +4.15%
Liabilities and Equity 277M USD -0.41%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -47.6M USD -54%
Net Cash Provided by (Used in) Financing Activities 96.2M USD +97.7%
Net Cash Provided by (Used in) Investing Activities 41.8M USD
Common Stock, Shares Authorized 900M shares 0%
Common Stock, Shares, Issued 71.1M shares +20%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 90.3M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 28.2M USD -46.3%
Deferred Tax Assets, Valuation Allowance 130M USD +32.8%
Deferred Tax Assets, Gross 132M USD +31.6%
Operating Lease, Liability 10.8M USD -13.7%
Depreciation 266K USD
Payments to Acquire Property, Plant, and Equipment 175K USD +192%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -135M USD +29.7%
Lessee, Operating Lease, Liability, to be Paid 14.8M USD -16.6%
Property, Plant and Equipment, Gross 1.08M USD +6.17%
Operating Lease, Liability, Current 1.05M USD +5.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 2.14M USD -17.1%
Lessee, Operating Lease, Liability, to be Paid, Year One 2.07M USD -5.69%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 4.04M USD -23.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 2.2M USD -7.99%
Deferred Tax Assets, Operating Loss Carryforwards 76.8M USD +45.4%
Unrecognized Tax Benefits 2.25M USD +20.3%
Lessee, Operating Lease, Liability, to be Paid, Year Four 2.27M USD +3%
Operating Lease, Payments 400K USD +300%
Additional Paid in Capital 808M USD +21.9%
Deferred Tax Assets, Net of Valuation Allowance 2.11M USD -15.1%
Share-based Payment Arrangement, Expense 22.9M USD -19.8%